Change in fast walking speed preceding death: results from a prospective longitudinal cohort study.
Séverine Sabia, Julien Dumurgier, Béatrice Tavernier, Jenny Head, Christophe Tzourio, Alexis Elbaz

To cite this version:
Change in Fast Walking Speed Preceding Death: Results From a Prospective Longitudinal Cohort Study

Séverine Sabia,1 Julien Dumurgier,2–4 Béatrice Tavernier,5 Jenny Head,1 Christophe Tzourio,6 and Alexis Elbaz2,3

1Department of Epidemiology and Public Health, University College London.
2Institut National de la Santé et de la Recherche Médicale U1018, Centre for Research in Epidemiology and Population Health, UMRS 1018, F-94807, Villejuif, France.
3University Paris-11, Villejuif, France.
4Memory Clinical Center Paris Nord-IDF, Fernand Widal Hospital, Paris, France.
5Department of Geriatrics, CHU Dijon, Dijon, France.
6Institut National de la Santé et de la Recherche Médicale U708, University of Bordeaux-Segalen, France.

Address correspondence to Séverine Sabia, PhD, Department of Epidemiology and Public Health, University College London, 1–19 Torrington Place, London WC1E 6BT, UK. Email: s.sabia@ucl.ac.uk

Background. Walking speed (WS) predicts mortality. However, it is unclear if decline in WS increases prior to death. We examined whether (a) WS declined faster in persons who died during the follow-up compared with those who remained alive and (b) adding change in WS to a model including age, sex, and baseline WS improved prediction of mortality.

Methods. Data are from 4,016 participants of the Dijon center of the Three-City study (France), aged 65–85 years. Fast WS (FWS) was measured up to five times over a 12-year period. Mortality was ascertained until 2012.

Results. Linear mixed models using a backward time scale showed that FWS declined faster in 908 participants who died during the follow-up (annual change = −0.031 m/s) than in those who survived (−0.021 m/s), corresponding to a difference of −0.009 (95% confidence interval = −0.013 to −0.005) m/s. Compared with “normal” change in FWS (annual change ≥−0.04 m/s), “substantial” decline (<−0.08 m/s) was associated with a 1.4-fold greater risk of mortality (hazards ratio = 1.40, confidence interval = 1.02–1.92) and small decline (−0.08 to −0.04 m/s) with a 1.2-fold greater risk (hazards ratio = 1.18, confidence interval = 0.89–1.57). The net reclassification index when adding these categories of change in FWS to the model adjusted for age, sex, and baseline FWS was 19.0% (0.6, 36.8%).

Conclusion. Participants who died during the follow-up had a steeper decline in FWS than the others. Both baseline FWS and FWS decline predict mortality.

Key Words: Physical function—Gait—Longevity.

Received September 11, 2012; Accepted May 29, 2013

Decision Editor: Stephen Kritchevsky, PhD

Walking speed (WS) is a robust predictor of mortality (1,2). A pooled analysis concluded that age, sex, and WS predicted mortality, as well as a more complete set of variables (age, sex, diseases, body mass index, systolic blood pressure, and hospitalization) (2). Most studies, with a few notable exceptions where change in WS over 1 or 2 years was analyzed (3–5), have examined whether a single WS measure predicts subsequent mortality. It remains unclear whether decline in WS is associated with risk of mortality.

Investigation into the cognitive trajectories of older adults provides evidence of a rapid decline in cognitive function preceding death (6,7). Underlying conditions (dementia and stroke) may play a role in some persons, but the accumulation of brain pathology or other biologic changes may also be involved (7,8). The extent to which terminal decline exists for physical functioning remains little explored (8,9). Using up to five measures of fast WS (FWS) over 12 years in individuals aged 65–85 years, we examined whether (a) FWS declined more rapidly in persons who died during follow-up compared with those who remained alive and (b) adding FWS decline to a model including age, sex, and baseline FWS improved prediction of mortality.

Methods

Study Population

The 3C study is a prospective cohort study conducted in three French cities (Bordeaux, Dijon, and Montpellier) (10). Electoral rolls were used to invite community dwellers aged 65 years or more (recruitment rate = 37%). This
study is based on data collected in Dijon (n = 4931), where a specific study on physical functioning was conducted. After baseline (wave 0, 1999–2001), participants were seen approximately every 2 years; 6 waves of data collection have taken place until 2012 in addition to the baseline assessment. At each wave (except wave 3 that consisted in a questionnaire), participants up to 85 years of age were invited to the study center for a clinical examination, whereas older participants were seen at home; however, to maximize participation, all participants were offered the opportunity of being seen at home. The study protocol was approved by the Ethical Committee of the University Hospital of Kremlin-Bicêtre; all participants gave informed consent.

Measures
WS was measured at baseline and at 4 (2003–2004, wave 2), 8 (2007–2008, wave 4), 10 (2009–2010, wave 5), and 12 years (2011–2012, wave 6) later, among participants up to 85 years of age who attended the study center (Figure 1). WS was measured at the study center using two photoelectric cells connected to a chronometer placed in a corridor 6 m apart. Two tests were carried out; participants were first asked to walk at their “usual” speed and then at “fast” speed, ie, as fast as they could without running. For wave 6, a home measure was added using portable photoelectric cells (n = 202); WS was measured over a 6 m distance in 89% cased and between 3.5 and 5 m in 11% cases. WS was computed as 6 m divided by time taken to complete the test in seconds. In a test–retest study, the intraclass correlation coefficient (SE) was 0.84 (0.02) for usual and 0.92 (0.02) for FWS (11). Given similar results for both measures, the higher reliability of FWS, and a markedly larger decline over time of FWS compared with usual WS (12), all results are presented using the former measure.

Mortality was available until 2012. Participants were contacted at each wave, and relatives and personal physicians of those who could not be reached were contacted to obtain information on their vital status.
Information on other covariates (disability, falls, sociodemographic, anthropometric, health behaviors, diseases, depressive symptoms, and cognition) is presented as Supplementary Material.

Statistical Methods

We excluded from the analyses participants with health conditions associated with marked gait impairment (recent hip fracture, parkinsonism, dementia, and disabling stroke; see Supplementary Table 1 for sensitivity analyses including these participants). Participants’ baseline characteristics are presented as a function of vital status at the end of follow-up and sex-specific tertiles of baseline FWS. Two sets of analyses were performed.

1. To compare change in FWS among deceased and non-deceased participants, change in FWS preceding death or end of the follow-up was estimated using linear mixed models with the intercept and slope as random effects and a backward time scale [7, 13]. In contrast to a positive scale starting at baseline, this approach does not assume that FWS trajectories continue after death. The starting time point \( t = 0 \) was (a) date of wave 6 for participants with FWS data at wave 6, (b) date of death for participants whose FWS was assessed at the last wave before death, (c) the midpoint between the date at which FWS was last measured and date of next wave for other participants. The time scale was defined backward from this starting point until the first FWS measure.

Vital status was included as a covariate in the linear mixed model to examine change in FWS as a function of vital status. First we modeled FWS as a function of vital status, age at \( t = 0 \), sex, time (in years), vital status \( \times \) time, and age at \( t = 0 \) \( \times \) time (Model 1). The regression coefficient of the vital status \( \times \) time interaction corresponds to the mean difference in annual change in FWS between deceased and non deceased participants.

We then included additional covariates associated with FWS and vital status (Model 2). For time-invariant variables (age, sex, height, education, smoking, and homocysteine), we included their main effect and interaction with time. Time-varying variables (body mass index, physical activity, coronary/peri pheral artery disease, diabetes, mental state examination score, lipid-lowering, antihypertensive, and psychotropic medications) were entered as main effects; in further analyses, we included their interactions with time.

We investigated whether delay between the last FWS measure and death or end of follow-up had an effect on the estimate of change in FWS by repeating the analyses in participants for whom a FWS measure was available in the last 2 or 4 years before death or end of follow-up.

FWS was not available for all participants at each wave. Reasons for missingness included death, age greater than 85 years, conditions associated with marked gait impairment, home interviews, and loss to follow-up. To investigate the influence of missing data, we used multiple imputation (Supplementary Methods).

2. To assess whether adding change in FWS to a model including age, sex, and baseline FWS improved the prediction of mortality, we estimated annual change in FWS using ordinary least squares regression for participants with FWS measures at the first 2 waves \( (5, 14) \). Standardized measures of baseline FWS and change in FWS were entered successively in an age- and sex-adjusted Cox proportional hazards model. In supplementary analyses, we entered FWS at wave 2 and checked whether adding change between baseline and wave 2 or baseline FWS improved prediction of mortality.

We repeated this analysis using categories of change in FWS based on two different definitions based on a distribution-based method \((15)\): (a) categories previously defined for usual WS \( (16) \) were “substantial” decline, less than \(-0.08 \text{ m/s}; \) “small” decline, \(-0.08 \text{ to } -0.04 \text{ m/s}; \) and “normal” change, more than or equal to \(-0.04 \text{ m/s}; \) (b) categories based on distribution of FWS in our population were “substantial” decline, less than \(-0.5 \times \text{ SD} \) of baseline FWS \( (-0.14 \text{ m/s}); \) “small” decline, \(-0.05 \text{ SD } \leq \text{ change } < -0.02 \text{ SD } (-0.14 \text{ to } -0.06 \text{ m/s}); \) and “normal” change, more than or equal to \(-0.02 \text{ SD } (-0.06 \text{ m/s}). \) Compared with a continuous measure of change, an advantage of these cutoffs is that they may be more easy to implement in the clinical setting to identify persons with marked decline in whom preventive strategies may be useful.

To assess improvement in the model’s predictive value, we used an extension of the net reclassification improvement (NRI) for survival analysis that offers a simple way to assess improvement in risk reclassification in the context of comparing two models \((17)\); 95% confidence intervals (CI) were computed using a bootstrap approach.

In order to examine whether change in FWS predicts both short- and long-term mortalities, we repeated these analyses by stratifying the follow-up period in two periods: the first 4 years following the last FWS measure and the years following this 4-year period.

RESULTS

Sample Description

Among 4,285 participants eligible at baseline, 4,016 participants with at least 1 FWS measure during follow-up compose the study population \((\text{Figure 1})\). Participants without FWS measures \((n = 269)\) were older and more disabled at baseline \((p < .001)\). Of the 4,016 participants, 908 died during the follow-up, 498 reached their 86th birthday during the study period, 1,250 stopped coming to the study center or dropped out from the study, and 256 developed conditions that strongly affected gait. Of participants included in the
Table 1. Baseline Characteristics of the Participants by Vital Status at the End of the Follow-up and Baseline Sex-Specific Tertiles of Fast Walking Speed (FWS)

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Overall (n = 4,016)</th>
<th>Alive (n = 3,108)</th>
<th>Dead (n = 908)</th>
<th>P&lt;sup&gt;†&lt;/sup&gt;</th>
<th>T1 (n = 1,256)</th>
<th>T2 (n = 1,258)</th>
<th>T3 (n = 1,197)</th>
<th>P&lt;sup&gt;†&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (M, SD)</td>
<td>73.4 (4.7)</td>
<td>72.7 (4.3)</td>
<td>75.7 (4.9)</td>
<td>&lt;.0001</td>
<td>75.3 (4.7)</td>
<td>73.2 (4.5)</td>
<td>71.7 (4.2)</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Women</td>
<td>61.7</td>
<td>65.8</td>
<td>47.2</td>
<td>&lt;.0001</td>
<td>60.8</td>
<td>65.5</td>
<td>58.6</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Primary school or less</td>
<td>34.7</td>
<td>34.6</td>
<td>34.8</td>
<td>.93</td>
<td>44.2</td>
<td>34.2</td>
<td>24.2</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>BMI ≥30 kg/m²</td>
<td>13.5</td>
<td>12.9</td>
<td>15.4</td>
<td>.007</td>
<td>20.3</td>
<td>12.3</td>
<td>7.7</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Height, cm (M, SD)</td>
<td>161.7 (8.7)</td>
<td>161.4 (8.6)</td>
<td>163.0 (9.2)</td>
<td>.79</td>
<td>160.48 (8.9)</td>
<td>161.26 (8.7)</td>
<td>165.53 (8.5)</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Low physical activity</td>
<td>23.5</td>
<td>22.1</td>
<td>29.3</td>
<td>&lt;.0001</td>
<td>30.3</td>
<td>20.7</td>
<td>19.5</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Grams of alcohol/wk (M, SD)</td>
<td>12.1 (13.7)</td>
<td>11.5 (13.3)</td>
<td>14.4 (15.6)</td>
<td>.60</td>
<td>12.1 (14.3)</td>
<td>11.5 (13.2)</td>
<td>12.8 (13.6)</td>
<td>.10</td>
</tr>
<tr>
<td>Smoking ≥20 pack-years</td>
<td>16.5</td>
<td>14.3</td>
<td>24.6</td>
<td>&lt;.0001</td>
<td>17.4</td>
<td>16.0</td>
<td>16.2</td>
<td>.01</td>
</tr>
<tr>
<td>Coronary artery disease</td>
<td>10.2</td>
<td>8.4</td>
<td>16.3</td>
<td>&lt;.0001</td>
<td>13.9</td>
<td>9.1</td>
<td>7.4</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Peripheral artery disease</td>
<td>3.2</td>
<td>2.1</td>
<td>6.9</td>
<td>&lt;.0001</td>
<td>4.8</td>
<td>2.3</td>
<td>2.5</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Antihypertensive treatment</td>
<td>47.2</td>
<td>44.2</td>
<td>57.0</td>
<td>&lt;.0001</td>
<td>57.1</td>
<td>45.2</td>
<td>39.0</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>7.6</td>
<td>6.7</td>
<td>10.2</td>
<td>.003</td>
<td>9.9</td>
<td>6.7</td>
<td>6.1</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Homocysteine, µmol/L (M, SD)</td>
<td>14.9 (5.6)</td>
<td>14.5 (4.9)</td>
<td>16.3 (7.2)</td>
<td>&lt;.0001</td>
<td>15.8 (5.9)</td>
<td>14.56 (5.1)</td>
<td>14.3 (5.6)</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Lipid-lowering drugs</td>
<td>33.6</td>
<td>34.3</td>
<td>30.5</td>
<td>.17</td>
<td>34.2</td>
<td>35.3</td>
<td>31.3</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>MMSE score (M, SD)</td>
<td>27.5 (1.9)</td>
<td>27.5 (1.9)</td>
<td>27.2 (1.9)</td>
<td>.02</td>
<td>27.0 (2.4)</td>
<td>27.6 (1.8)</td>
<td>27.8 (1.7)</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Psychotropic drugs</td>
<td>25.5</td>
<td>24.0</td>
<td>28.5</td>
<td>.02</td>
<td>33.4</td>
<td>24.0</td>
<td>18.6</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Depressive symptoms&lt;sup&gt;§&lt;/sup&gt;</td>
<td>13.1</td>
<td>12.4</td>
<td>14.1</td>
<td>.39</td>
<td>18.1</td>
<td>11.4</td>
<td>9.5</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>NSAIDs&lt;sup&gt;‡&lt;/sup&gt;</td>
<td>14.9</td>
<td>15.1</td>
<td>14.5</td>
<td>.72</td>
<td>19.5</td>
<td>14.4</td>
<td>10.6</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Disability**</td>
<td>5.0</td>
<td>3.6</td>
<td>9.0</td>
<td>&lt;.0001</td>
<td>9.7</td>
<td>3.4</td>
<td>1.6</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Fall in the preceding year</td>
<td>16.9</td>
<td>16.2</td>
<td>19.9</td>
<td>.003</td>
<td>20.1</td>
<td>17.7</td>
<td>12.7</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Walking speed, m/s (M, SD)</td>
<td>1.5 (0.3)</td>
<td>1.6 (0.3)</td>
<td>1.5 (0.3)</td>
<td>&lt;.0001</td>
<td>1.2 (0.2)</td>
<td>1.5 (0.1)</td>
<td>1.9 (0.2)</td>
<td>&lt;.0001</td>
</tr>
</tbody>
</table>

Notes: ADL = activities of daily living; IADLs = instrumental activities of daily living; T = tertile; M = mean; SD = standard deviation; BMI = body mass index; MMSE = mini-mental state examination; NSAIDs = nonsteroidal anti-inflammatory drugs. *Percents unless otherwise stated.

<sup>†</sup>4,016 participants with ≥1 FWS measure during follow-up.

<sup>‡</sup>Analysis of covariance (continuous variables) or Cochran-Mantel-Haenszel chi-square test (categorical variables) age adjusted and sex adjusted.

<sup>§</sup>Cutoffs: men: T1: ≤1.50 m/s; T2: 1.51–1.82 m/s; T3: >1.82 m/s; women: T1: ≤1.30 m/s; T2: 1.31–1.50 m/s; T3: >1.50 m/s.

<sup>¶</sup>Linear regression analysis of covariance with continuous walking speed as the outcome, age- and sex-adjusted.

<sup>**</sup>Disabled for mobility and IADLs/ADLs. Missing for 133 (relation with vital status) and 124 (relation with walking speed) subjects.

Table 2. Fixed Effects for Multilevel Models of Change in Fast Walking Speed before Death or End of Follow-up

<table>
<thead>
<tr>
<th>Fixed Effects</th>
<th>Estimate (95% CI)</th>
<th>P</th>
<th>Estimate (95% CI)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intercept&lt;sup&gt;†&lt;/sup&gt;</td>
<td>1.551 (1.537, 1.567)</td>
<td>&lt;.0001</td>
<td>1.581 (1.560, 1.603)</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Sex (women vs men)</td>
<td>-0.241 (-0.257, -0.226)</td>
<td>&lt;.0001</td>
<td>-0.192 (-0.215, -0.170)</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Age (centered at 80 y), per 10-y increment</td>
<td>-0.152 (-0.174, -0.131)</td>
<td>&lt;.0001</td>
<td>-0.152 (-0.174, -0.131)</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Vital status (dead vs alive)</td>
<td>-0.090 (-0.113, -0.067)</td>
<td>&lt;.0001</td>
<td>-0.074 (-0.097, -0.051)</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Time (annual change)</td>
<td>-0.021 (-0.022, -0.020)</td>
<td>&lt;.0001</td>
<td>-0.020 (-0.022, -0.018)</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Time × age</td>
<td>-0.006 (-0.009, -0.002)</td>
<td>.002</td>
<td>-0.006 (-0.010, -0.003)</td>
<td>.0004</td>
</tr>
<tr>
<td>Time × vital status</td>
<td>-0.009 (-0.013, -0.005)</td>
<td>&lt;.0001</td>
<td>-0.009 (-0.014, -0.005)</td>
<td>&lt;.0001</td>
</tr>
</tbody>
</table>

Notes: CI = confidence interval. *Adjusted for sex, age, vital status, education, height, smoking ≥20 pack-years, homocysteine, time, time × age, time × vital status, time × education, time × height, time × smoking ≥20 pack-years, time × homocysteine, time-dependent variables (body mass index, physical activity, coronary/peripheral artery disease, antihypertensive drugs, diabetes, lipid-lowering drugs, mini-mental state examination score, psychotropic drugs).

<sup>†</sup>In model 1, the intercept corresponds to the average walking speed at the end of follow-up for men alive and aged 80 y. In model 2, the intercept corresponds to the average walking speed at the end of follow-up for men alive and aged 80 y, with primary school level, body mass index = 25 kg/m², height = 165 cm, physically active, smoking <20 pack-years, no health conditions, mini-mental state examination = 30, homocysteine = 14 µmol/L.
Decline in FWS as a Predictor of Mortality

These analyses are based on 2,094 participants with FWS measures at the 2 first waves, among whom 308 (14.7%) died. The mean baseline FWS was 1.580 (SD = 0.299) m/s, and mean annual change in FWS was −0.023 (SD = 0.065) m/s. Table 3 shows hazards ratio (HR) for models adjusted successively for baseline FWS and change in FWS. In an age- and sex-adjusted model, an increase of one SD in FWS at baseline was associated with a 21% lower mortality (HR = 0.79, CI: 0.70–0.90). When change in FWS was added, both baseline FWS (HR = 0.71, CI: 0.62–0.82) and change in FWS (HR = 0.80, CI: 0.71–0.90) independently predicted death. The NRI when adding change in FWS to the model including age, sex, and baseline FWS was 27.9% (CI: 9.3, 44.5%).

Analysis using categories of change in FWS defined by Kwon and colleagues (16) for usual WS showed that, compared with normal change (≥−0.04 m/s, n = 1,359, 184 deaths), substantial decline (<−0.08 m/s, n = 322, 58 deaths) was associated with a 1.4-fold greater risk of mortality (HR = 1.40, CI: 1.02–1.92) and small decline (−0.08 to −0.04 m/s, n = 413, 66 deaths) with a 1.2-fold greater risk (HR = 1.18, CI: 0.89–1.57; Table 3). The NRI when adding these categories of change in FWS to the model adjusted for age, sex, and baseline FWS was 19.0% (0.6, 36.8%). Analyses using alternative categories of change defined based on the distribution of FWS in our population (small decline: −0.14 to −0.06 m/s, n = 403, 67 deaths; substantial decline: <−0.14 m/s, n = 97, 21 deaths; normal change: ≥−0.06, n = 1,594, 220 deaths) showed similar trends. The NRI when adding these categories of change in FWS to the model adjusted for age, sex, and baseline FWS was 16.3% (−2.6, 33.3%). There was no interaction (p > .67) between baseline FWS and categories of change in FWS, suggesting that the effect of change in FWS was evident at all levels of baseline FWS.

Analyses stratified by follow-up period showed that baseline FWS was associated both with short- and long-term mortalities, whereas the association with change in FWS was more pronounced in the first 4 years of follow-up, particularly when categories of change in FWS were used (Table 3).

Supplementary analysis (Supplementary Table 3) showed that in a model including age, sex and FWS at wave 2, baseline FWS or change in FWS between baseline and wave 2 were not associated with mortality and did not improve the predictive value of the model (all NRI not significantly different from 0).

**Discussion**

**Summary of the Results**

In this large cohort study of community-dwelling elderly persons aged 65–85 years with up to five assessments of FWS over 12 years, participants who died during the study experienced a steeper decline in FWS before death compared with those who remained alive. We examined whether this difference had
clinical implications and found that adding change in FWS to a survival model including age, sex, and baseline FWS improved the predictive performances of the model.

What This study Adds

There is robust evidence of an association between slower WS, when measured once, with subsequent mortality (1,2,18), but less is known about change in WS preceding death (1,2). Previous studies have examined the association between change in WS and risk of mortality (3–5,9) and showed that higher decline was associated with higher risk of mortality. Apart from one exception (9), these studies were smaller than the present one, and change in WS was examined over a maximum of 2 years while participants were followed for mortality over at most 8 years (3–5). In the Health ABC study (n = 2,364) (9), WS was assessed three times over 2 years and the follow-up period for mortality was of 10 years. Another study (n = 690) showed lower baseline scores and larger decline in a composite score of lower extremity function in 470 participants who died during a 12-year follow-up period (19). This study has several strengths: it is based on a large cohort of community-dwelling older adults; FWS was measured up to five times over 12 years; many potential confounders were assessed throughout follow-up. In addition to survival analyses similar to those previously carried out in other studies, we also used linear mixed models with a backward time scale to model change in FWS; this approach has been used to examine trajectories of health indicators preceding adverse outcomes (7,13), including motor (8) and cognitive decline (7).

Baseline FWS and change in FWS had independent effects on the risk of death. Although there was both a short- and a long-term association between baseline FWS and death, our findings suggest that change in FWS had a more pronounced effect on the risk of death in the short term than in the long term. In addition, FWS at wave 2, which results from baseline FWS and decline in FWS between waves 1 and 2, appears to be a good predictor of upcoming death, and baseline FWS or change in FWS between baseline and wave 2 did not improve prediction of mortality compared with a model including FWS at wave 2 only. This result is comparable with findings from one study showing that 1-year change in FWS does not provide additional prognostic information for dependence in activities of daily living beyond that available based on the last FWS measure (20). Our findings have three clinical implications: first, repeated assessments of FWS may help identify persons particularly at risk of adverse outcomes, even among those with normal baseline FWS; second, the advent of marked decline in FWS is suggestive of a higher risk of death in the relatively near future; third, if FWS is repeatedly measured, the last and more recent measure is sufficient to predict mortality. The identification of persons with marked motor decline should lead to assess their health status in order to identify possible causes and implement the corresponding therapeutic strategies.

As shown previously (12) and also found in the 3C Study, there is a greater decline and interindividual variability in fast than usual WS. This led us to use FWS for the analyses as it is expected that differences in decline across groups of people are more easily detectable by clinicians for this measure. There is no cutoff available for meaningful change

<table>
<thead>
<tr>
<th>Model*</th>
<th>Baseline FWS</th>
<th>Change in FWS (Cont)</th>
<th>Normal Change</th>
<th>Small Decline</th>
<th>Substantial Decline</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HR (95% CI)</td>
<td>HR (95% CI)</td>
<td>HR (95% CI)</td>
<td>HR (95% CI)</td>
<td>HR (95% CI)</td>
</tr>
<tr>
<td>Full follow-up period (n = 2,094; 308 deaths)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M1: age, sex, baseline FWS (Cont)</td>
<td>0.79 (0.70, 0.90)</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>M2: M1 + change in FWS (Cont)</td>
<td>0.71 (0.62, 0.82)</td>
<td>0.80 (0.71, 0.90)</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>M3: M1 + change in FWS (Cat1)*</td>
<td>0.76 (0.66, 0.86)</td>
<td>—</td>
<td>1.00 (ref)</td>
<td>1.18 (0.89, 1.57)</td>
<td>1.40 (1.02, 1.92)</td>
</tr>
<tr>
<td>M3: M1 + change in FWS (Cat2)*</td>
<td>0.75 (0.66, 0.85)</td>
<td>—</td>
<td>1.00 (ref)</td>
<td>1.24 (0.94, 1.65)</td>
<td>1.94 (1.22, 3.11)</td>
</tr>
<tr>
<td>Four first years of follow-up (n = 2,094; 93 deaths)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M1: age, sex, baseline FWS (Cont)</td>
<td>0.81 (0.65, 1.03)</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>M2: M1 + change in FWS (Cont)</td>
<td>0.72 (0.56, 0.92)</td>
<td>0.77 (0.63, 0.94)</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>M3: M1 + change in FWS (Cat1)*</td>
<td>0.74 (0.58, 0.94)</td>
<td>—</td>
<td>1.00 (ref)</td>
<td>1.53 (0.93, 2.54)</td>
<td>2.05 (1.19, 3.53)</td>
</tr>
<tr>
<td>M3: M1 + change in FWS (Cat2)*</td>
<td>0.74 (0.59, 0.94)</td>
<td>—</td>
<td>1.00 (ref)</td>
<td>1.62 (1.00, 2.63)</td>
<td>2.49 (1.15, 5.39)</td>
</tr>
<tr>
<td>Excluding the four first years of follow-up (n = 1,921; 215 deaths)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M1: age, sex, baseline FWS (Cont)</td>
<td>0.78 (0.67, 0.91)</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>M2: M1 + change in FWS (Cont)</td>
<td>0.71 (0.60, 0.83)</td>
<td>0.81 (0.71, 0.93)</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>M3: M1 + change in FWS (Cat1)*</td>
<td>0.77 (0.65, 0.90)</td>
<td>—</td>
<td>1.00 (ref)</td>
<td>1.05 (0.74, 1.49)</td>
<td>1.17 (0.79, 1.73)</td>
</tr>
<tr>
<td>M3: M1 + change in FWS (Cat2)*</td>
<td>0.75 (0.64, 0.88)</td>
<td>—</td>
<td>1.00 (ref)</td>
<td>1.10 (0.77, 1.56)</td>
<td>1.73 (0.96, 3.11)</td>
</tr>
</tbody>
</table>

Notes: CI = confidence interval; Cont = continuous; Cat = categorical; M = model; HR = hazards ratio; ref = reference. *Continuous variables are standardized: the HR for baseline FWS corresponds to an increment of 0.299 m/s; the HR for FWS change corresponds to an increase in 1 y change FWS of 0.065 m/s.
†Categorical definition 1 (Cat1) of annual change in FWS: substantial decline: <−0.08 m/s; small decline: −0.08 to −0.04 m/s; normal: ≥−0.04 m/s.
‡Categorical definition 2 (Cat2) of annual change in FWS: substantial decline: <−0.14 m/s; small decline: −0.06 to −0.14 m/s; normal: ≥−0.06 m/s.

*p value comparing the predictive values of M2/M3 with M1.
in FWS, so we used the cutoffs proposed by Kwon and colleagues (16) for usual WS to identify clinically meaningful change and they appeared to be relevant with respect to mortality in our study. The alternative method that we used to define categories of change in FWS based on cut-points derived from a distribution-based method showed slightly stronger associations with mortality, although CIs were larger due to the small number of participants with substantial decline. Further research is thus needed to replicate these analyses and define cutoffs for meaningful change for FWS.

**Potential Mechanisms**

Walking is a complex activity involving several (eg, musculoskeletal, pulmonary, neurological, and cardiovascular) systems (2). Mechanisms underlying the WS-mortality association are likely to be multifactorial. First, cardiovascular health is a common determinant of WS and longevity. WS has been associated with several cardiovascular outcomes or risk factors, including cardiovascular death (18), stroke (21), diabetes (22), homocysteine (23), hypertension (11), arterial stiffness (24), coronary artery calcification (25), and intima-media thickness (26). In this study, after adjustment for cardiovascular risk factors and diseases, the association between WS decline and mortality remained robust. Nevertheless, WS decline could reflect underlying cardiovascular conditions not taken into account, and imperfect measurement of cardiovascular risk factors may have resulted in residual confounding. The number of events did not allow us to perform analyses by cause of death, which may be useful in future studies. Second, slow WS is a risk factor for dependency (27), which predicts mortality (28) and could represent an intermediate factor. Third, WS decline may be an early indicator of loss of muscle strength (12,29) or sarcopenia (30) and frailty (31), which predict mortality (31). Inflammation plays a role in frailty (32,33), and increased levels of inflammatory markers have been shown to be associated with slower WS (34,35) and higher risk of mortality (36,37). Thus, inflammatory processes could be involved in this association (38).

Investigation into cognitive trajectories of older adults provides evidence of a more market decline in cognitive function in the years before death, irrespective of premorbid cognitive level (6,7). When this rapid decline in cognitive function is gradual in the years preceding death, it is referred to “terminal decline,” and when this decline is interrupted by precipitous acceleration of the decline, it is referred to “terminal drop” (39). The extent to which a similar phenomenon exists for physical functioning has been little explored (8). Because participants who died during the follow-up were more likely to reach their 86th birthday during the follow-up, FWS measures were more likely to be missing in the few years preceding death; therefore, we could not distinguish whether there was a gradual decline (terminal decline) or an abrupt change (terminal drop) before death usually assessed using a quadratic term for change over time or change point models (39), but we were only able to study change in FWS as a linear function of time due to those missing FWS before death. Higher resolution data with shorter intervals between WS measures are needed to address this question.

In order to assess whether the greater FWS decline observed in the years preceding death was confounded by cognitive decline, analyses were adjusted for cognitive status (mini-mental state examination) modeled as a time-varying variable, and the association remained unchanged. Declines in cognitive function and FWS before death might represent two different aspects of the same process and suggest that different physiological functions exhibit faster decline in the years preceding death. The parallelism between declines in cognitive and physical functioning is important and further research is required to assess the extent to which this finding extends to other physical measures (strength and balance).

**Study Limitations**

The main limitation of our analyses is related to participants who dropped out during follow-up. One of the main reasons was that FWS was not measured in participants who were interviewed at home at all waves. Nevertheless, other measures (eg, disability, falls, and cognition) linked to functional health were assessed in these persons and used in analyses based on multiple imputation that yielded results that were in agreement with our main conclusion. In addition, FWS was not measured after 85 years, so we cannot test whether our findings on change in FWS can be extended to older ages. Finally, participants who accepted to participate to the study were community-dwelling, well-functioning older people. Although this is likely to lead to an underestimation of the incidence of events such as death, it has been shown that the relation between an exposure and mortality during follow-up is less likely to be biased (40).

**Conclusion**

This study shows that FWS decline is greater in individuals aged 65–85 years who will die in the next few years than in those who remain alive and that FWS change predicts mortality independently of baseline FWS. Therefore, repeated FWS measures may be clinically useful in elderly people and may help identify persons with marked motor decline in whom health assessments and preventive strategies may be useful. Future research should measure FWS on several occasions with shorter intervals between measures, to detect when FWS trajectories of participants at higher risk of mortality deviate from those at lower risk.

**Supplementary Material**

Supplementary material can be found at: [http://biomedgerontology.oxfordjournals.org/](http://biomedgerontology.oxfordjournals.org/)
Funding


Acknowledgments

We thank the study participants and persons involved in data collection and study coordination. We thank Archana Singh-Manoux for useful comments. We thank Michael J. Pencina (Boston University) for providing a SAS macro in order to compute the NRI in the context of survival analysis.

References